PacBio Announces Second Quarter 2025 Financial Results
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025 Q2…
Press releases
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider…
PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications
Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality,…
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer…
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025
MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results…
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene
Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centers MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading…
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent…
PacBio Announces First Quarter 2025 Financial Results
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1…
PacBio Announces First Quarter 2025 Financial Results
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1…
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
Collaboration leverages HiFi’s unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE)…
PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry
Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE)…
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa
International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) — The…
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE)…
Search